These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 25945406)
1. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Sim JJ; Bhandari SK; Shi J; Reynolds K; Calhoun DA; Kalantar-Zadeh K; Jacobsen SJ Kidney Int; 2015 Sep; 88(3):622-32. PubMed ID: 25945406 [TBL] [Abstract][Full Text] [Related]
2. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M; Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745 [TBL] [Abstract][Full Text] [Related]
3. Prognostic importance of baseline and serial changes in microalbuminuria in patients with resistant hypertension. Salles GF; Cardoso CR; Fiszman R; Muxfeldt ES Atherosclerosis; 2011 May; 216(1):199-204. PubMed ID: 21315356 [TBL] [Abstract][Full Text] [Related]
4. Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension. Bhandari SK; Shi J; Molnar MZ; Rasgon SA; Derose SF; Kovesdy CP; Calhoun DA; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ Respirology; 2016 Nov; 21(8):1486-1492. PubMed ID: 27427469 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study. Shireman TI; Mahnken JD; Phadnis MA; Ellerbeck EF BMC Cardiovasc Disord; 2016 Mar; 16():60. PubMed ID: 27012911 [TBL] [Abstract][Full Text] [Related]
6. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894 [TBL] [Abstract][Full Text] [Related]
7. Assessing outcomes to determine whether symptoms related to hypertension justify renal artery stenting. Modrall JG; Rosero EB; Timaran CH; Anthony T; Chung J; Valentine RJ; Trimmer C J Vasc Surg; 2012 Feb; 55(2):413-9; discussion 419-20. PubMed ID: 22133456 [TBL] [Abstract][Full Text] [Related]
8. Retrospective and prospective research on hypertension-related end-organ damage. Perloff D J Cardiovasc Pharmacol; 1994; 24 Suppl A():S1-5. PubMed ID: 7603071 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study. Smith SM; Huo T; Delia Johnson B; Bittner V; Kelsey SF; Vido Thompson D; Noel Bairey Merz C; Pepine CJ; Cooper-Dehoff RM J Am Heart Assoc; 2014 Feb; 3(1):e000660. PubMed ID: 24584740 [TBL] [Abstract][Full Text] [Related]
10. Left atrial enlargement and risk of ischemic stroke in elderly treated hypertensive patients. Pierdomenico SD; Pierdomenico AM; Di Carlo S; Di Tommaso R; Cuccurullo F Am J Hypertens; 2014 Sep; 27(9):1179-84. PubMed ID: 24682334 [TBL] [Abstract][Full Text] [Related]
11. Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension. Fatemi O; Goa C; Faselis C; Kokkinos P; Papademetriou V J Clin Hypertens (Greenwich); 2016 Jan; 18(1):33-9. PubMed ID: 26440866 [TBL] [Abstract][Full Text] [Related]
12. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Agarwal R Clin J Am Soc Nephrol; 2009 Apr; 4(4):830-7. PubMed ID: 19339424 [TBL] [Abstract][Full Text] [Related]
13. Prediction of cardiovascular and renal risk among patients with apparent treatment-resistant hypertension in the United States using machine learning methods. Bakris G; Lin PP; Xu C; Chen C; Ashton V; Singhal M J Clin Hypertens (Greenwich); 2024 May; 26(5):500-513. PubMed ID: 38523465 [TBL] [Abstract][Full Text] [Related]
14. Patient characteristics and outcomes by GN subtype in ESRD. O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830 [TBL] [Abstract][Full Text] [Related]
15. Impact of severity of renal dysfunction on determinants of in-hospital mortality among patients undergoing percutaneous coronary intervention. Parikh PB; Jeremias A; Naidu SS; Brener SJ; Lima F; Shlofmitz RA; Pappas T; Marzo KP; Gruberg L Catheter Cardiovasc Interv; 2012 Sep; 80(3):352-7. PubMed ID: 22566286 [TBL] [Abstract][Full Text] [Related]
16. Resistant hypertension is associated with an increased cardiovascular risk compared to patients controlled on a similar multi-drug regimen. Leiba A; Yekutiel N; Chodick G; Wortsman J; Angel-Korman A; Weinreb B J Hum Hypertens; 2023 Jul; 37(7):542-547. PubMed ID: 35999382 [TBL] [Abstract][Full Text] [Related]
17. The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. De Nicola L; Minutolo R; Chiodini P; Borrelli S; Zoccali C; Postorino M; Iodice C; Nappi F; Fuiano G; Gallo C; Conte G; Kidney Int; 2012 Aug; 82(4):482-8. PubMed ID: 22622495 [TBL] [Abstract][Full Text] [Related]
18. Antihypertensive treatment, high triglycerides, and low high-density lipoprotein cholesterol and risk of ischemic heart disease mortality: a 16-year follow-up in the Copenhagen male study. Suadicani P; Hein HO; Gyntelberg F Metab Syndr Relat Disord; 2010 Jun; 8(3):215-22. PubMed ID: 20156073 [TBL] [Abstract][Full Text] [Related]
19. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Bangalore S; Fayyad R; Laskey R; Demicco DA; Deedwania P; Kostis JB; Messerli FH; Am J Med; 2014 Jan; 127(1):71-81.e1. PubMed ID: 24210549 [TBL] [Abstract][Full Text] [Related]
20. Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease. Bakris G; Chen C; Campbell AK; Ashton V; Haskell L; Singhal M Am J Hypertens; 2024 May; 37(6):438-446. PubMed ID: 38436491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]